SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations.
SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations.
复制标题
DOI：
10.3390/v13030392
复制
发表时间：
2021-03-01
期刊：
影响因子：
--
通讯作者：
Lipniacki T
中科院分区：
文献类型：
--
作者：
Grabowski F;Preibisch G;Giziński S;Kochańczyk M;Lipniacki T
新型SARS-CoV-2关注变体(VOC)- 2012012 /01（也称为B.1.1.7）于2020年9月20日首次在英国收集，是一个快速增长的谱系，在2021年1月占英国所有SARS-CoV-2基因组测序的86%。在2021年1月报告了至少50个基因组的46个国家中，有40个国家检测到了VOC。我们估计，相对于20A， VOC的复制优势在1.83-2.18 [95% CI: 1.71-2.40]范围内。EU1变异于2020年11月在英格兰占主导地位，在威尔士、苏格兰、丹麦和美国的范围为1.65-1.72 [95% CI: 1.46-2.04]。由于挥发性有机化合物可能会在全球范围内传播，因此监测其分子进化是很重要的。我们估计了VOC谱系获得的扩展突变的生长速率，发现spike中的L18F取代启动了快速生长的VOC亚品系。L18F取代具有重要意义，因为已经发现它会损害中和抗体的结合。值得关注的是由VOC获得的免疫逃逸突变：E484K， F490S, S494P（在spike的受体结合基序中）和Q677H， Q675H（在S1/S2边界的多碱基切割位点附近）。这些突变体可能会阻碍现有疫苗的效率，并随着感染后或疫苗诱导的血清流行率的增加而扩大。
The novel SARS-CoV-2 Variant of Concern (VOC)-202012/01 (also known as B.1.1.7), first collected in United Kingdom on 20 September 2020, is a rapidly growing lineage that in January 2021 constituted 86% of all SARS-CoV-2 genomes sequenced in England. The VOC has been detected in 40 out of 46 countries that reported at least 50 genomes in January 2021. We have estimated that the replicative advantage of the VOC is in the range 1.83–2.18 [95% CI: 1.71–2.40] with respect to the 20A.EU1 variant that dominated in England in November 2020, and in range 1.65–1.72 [95% CI: 1.46–2.04] in Wales, Scotland, Denmark, and USA. As the VOC strain will likely spread globally towards fixation, it is important to monitor its molecular evolution. We have estimated growth rates of expanding mutations acquired by the VOC lineage to find that the L18F substitution in spike has initiated a fast growing VOC substrain. The L18F substitution is of significance because it has been found to compromise binding of neutralizing antibodies. Of concern are immune escape mutations acquired by the VOC: E484K, F490S, S494P (in the receptor binding motif of spike) and Q677H, Q675H (in the proximity of the polybasic cleavage site at the S1/S2 boundary). These mutants may hinder efficiency of existing vaccines and expand in response to the increasing after-infection or vaccine-induced seroprevalence.
登录
查看更多内容
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
DOI：
10.1016/s0140-6736(21)00183-5
发表时间：
2021-02-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Sabino EC;Buss LF;Carvalho MPS;Prete CA Jr;Crispim MAE;Fraiji NA;Pereira RHM;Parag KV;da Silva Peixoto P;Kraemer MUG;Oikawa MK;Salomon T;Cucunuba ZM;Castro MC;de Souza Santos AA;Nascimento VH;Pereira HS;Ferguson NM;Pybus OG;Kucharski A;Busch MP;Dye C;Faria NR
通讯作者：
Faria NR
影响因子：
64.8
作者：
Collier DA;Ferreira IATM;Kotagiri P;Datir RP;Lim EY;Touizer E;Meng B;Abdullahi A;CITIID-NIHR BioResource COVID-19 Collaboration;Elmer A;Kingston N;Graves B;Le Gresley E;Caputo D;Bergamaschi L;Smith KGC;Bradley JR;Ceron-Gutierrez L;Cortes-Acevedo P;Barcenas-Morales G;Linterman MA;McCoy LE;Davis C;Thomson E;Lyons PA;McKinney E;Doffinger R;Wills M;Gupta RK
通讯作者：
Gupta RK
DOI：
10.1126/science.abe6230
发表时间：
2021-02-12
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Koenig PA;Das H;Liu H;Kümmerer BM;Gohr FN;Jenster LM;Schiffelers LDJ;Tesfamariam YM;Uchima M;Wuerth JD;Gatterdam K;Ruetalo N;Christensen MH;Fandrey CI;Normann S;Tödtmann JMP;Pritzl S;Hanke L;Boos J;Yuan M;Zhu X;Schmid-Burgk JL;Kato H;Schindler M;Wilson IA;Geyer M;Ludwig KU;Hällberg BM;Wu NC;Schmidt FI
通讯作者：
Schmidt FI
影响因子：
17.1
作者：
Qiao, Baofu;de la Cruz, Monica Olvera
通讯作者：
de la Cruz, Monica Olvera